COVER STORY / ADVERTISING FEATURE


separation and data analysis often require significant manual input, specialist expertise and tightly controlled conditions. Testing is also typically carried out in


batches, which can slow turnaround times and make it harder to respond to urgent clinical need. On top of this, differences in methods, systems and software have made it challenging to standardise processes and integrate mass spectrometry into everyday laboratory workflows. Taken together, these barriers have


meant that mass spectrometry has largely remained within specialist or reference laboratories, despite its potential to deliver much broader value across the NHS.


Automation unlocking potential The introduction of the cobas Mass Spec solution represents a fundamental shift in how mass spectrometry can be deployed within NHS laboratories. Ready-to-use reagent cassetes and


pre-prepared internal standards remove the need for time-intensive manual preparation, while a user-friendly interface simplifies day-to-day operation. Importantly, system setup and assay validation have been developed with routine clinical laboratories in mind, with compliance with IVD standards helping significantly streamline implementation. Crucially, the introduction of random-


access capability marks a turning point. Moving away from traditional batch-


mode workflows allows samples to be processed as they arrive, enabling faster turnaround times and greater responsiveness to clinical demand. At the same time, scalability has been


built into the system. With an assay menu spanning more than 60 analytes and a throughput of up to 100 tests per hour, laboratories can expand testing capacity without proportionally increasing operational burden. Taken together, these advances


reposition mass spectrometry – from a highly specialised technique to a practical, scalable solution for routine diagnostics.


Implementation at SWLP For SWLP, one of the UK’s largest pathology networks, the introduction of automated mass spectrometry is not just a technological upgrade, it is a strategic milestone. Serving a population of around 1.5 million people and processing over 50 million tests annually, the network operates at a significant scale. With demand continuing to rise, SWLP has set out a clear ambition within its five- year strategy: to remain at the forefront of scientific advancement in laboratory medicine, using technology and innovation to shape services and support the ongoing digitalisation of pathology. The installation


reliable results can remove uncertainty at critical points in the care pathway. Whether it’s adjusting a patient’s medication, confirming a diagnosis or ruling out a serious condition, having confidence in the result first time can make all the difference. For patients, that confidence translates into something simpler, but no less important: less waiting, fewer repeat tests and a clearer path forward. Inside the laboratory, the shift is just as


SWLP is already reporting meaningful reductions in turnaround times and error rates, driven by the system’s automation.


of the cobas Mass Spec solution brings that ambition to life. As the first NHS site to implement


the cobas Mass Spec solution, SWLP is uniquely positioned to explore what routine, scalable mass spectrometry can deliver – not only in theory, but in day- to-day clinical practice. Implementation has been carefully structured through a phased rollout, ensuring that training, validation and service integration are delivered in a controlled and sustainable way. This approach is supported by Roche Diagnostics’ dedicated change management programme, helping to embed new workflows while supporting laboratory teams through the transition. Initial testing is focused on aldosterone,


providing a foundation for subsequent expansion into immunosuppressant and steroid analysis. Over time, the test menu is expected to broaden significantly – encompassing applications such as low- level oestradiol testing and therapeutic drug monitoring. Even in the early stages of implementation, the impact is already being felt across the laboratory. Teams are reporting meaningful reductions in turnaround times and error rates, driven by the system’s automation and intuitive design. The familiar interface is enabling a broader range of staff to operate the platform confidently, reducing reliance on highly specialised expertise. Automation is also transforming


workflow efficiency. The ability to automatically rerun samples without waiting for the next batch removes a long- standing botleneck in mass spectrometry processes, while random access testing allows laboratories to respond more dynamically to clinical demand.


Delivering value Beyond operational efficiencies, the real impact of automated mass spectrometry is felt in the moments that mater most – when results are needed, decisions are made, and patients are waiting. For clinicians, faster access to highly


significant. By reducing manual processes, streamlining workflows and enabling flexibility, the system is helping to ease pressure on stretched teams and allowing laboratories to respond more dynamically to clinical demand. At a broader level, bringing this kind


of advanced testing in-house helps keep expertise, capability and care closer to the patient. In a system under increasing pressure, that combination of clinical confidence, operational resilience and improved patient experience is becoming ever more important.


Looking ahead The arrival of fully automated mass spectrometry at SWLP signals more than just faster testing – it represents a strategic shift in how the NHS can deliver high-value, patient-centred diagnostics. By embedding precision, reliability and scalability into routine workflows, laboratories are now equipped to provide results that clinicians can act on with confidence, supporting earlier interventions and more personalised treatment pathways. This capability has profound


implications for patient care. Detailed, high-quality mass spectrometry data enables clinicians to move beyond reactive decision-making, tailoring therapy with confidence and reducing the uncertainty that can drive repeat testing or unnecessary referrals. By combining advanced technology


with strategic vision, SWLP is showing how laboratories can evolve from service providers into proactive partners in patient care – seting a benchmark for the future of diagnostics across the NHS. PPi


Joanne Bradley MSc Regional Product Manager - cobas Mass Spec Solution +44 (0)7808647881 joanne.bradley@roche.com


Scan the QR code to visit Roche Diagnostics’ cobas Mass Spec solution website:


May 2026 WWW.PATHOLOGYINPRACTICE.COM 7


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52